OnCo
institutionsInstitution

The Mount Sinai Hospital / Tisch Cancer Institute

Mount Sinai is a New York academic centre with strengths in myeloma and cancer immunology.

Tisch Cancer Institute; myeloma (Jagannath), immunology (Merad, Bhardwaj), neoadjuvant immunotherapy.

Location
New York, US
Type
hospital
Newsweek 2026 oncology rank
#34
NCI designation
clinical
OnCo score
#41 · 48 points (26 Newsweek + 8 NCI + 14 from 7 linked objects) · ranking

Programmes

2top
  • Myeloma
  • Tumour immunology

People

7top
Joshua Brody
Director, Lymphoma Immunotherapy Program
LymphomaIn situ vaccinationBispecific antibodies

Developed in situ vaccination, turning a single injected lymphoma tumour into a vaccine against the rest.

Matthew D. Galsky
Director, Genitourinary Medical Oncology; Co-Director, Center of Excellence for Bladder Cancer
Bladder cancerImmunotherapyBladder preservation

Led trials that brought immunotherapy into bladder cancer and tested skipping cystectomy in responders.

Miriam Merad
Director, Marc and Jennifer Lipschultz Precision Immunology Institute; Chair, Department of Immunology and Immunotherapy
Myeloid cellsTumour-associated macrophagesSingle-cell immunology

Mapped how macrophages and dendritic cells in tumours suppress immunity, opening new immunotherapy targets.

Nina Bhardwaj
Director of Immunotherapy; Ward-Coleman Chair in Cancer Research
Dendritic cellsCancer vaccinesPersonalised neoantigen vaccines

Nina Bhardwaj is a dendritic-cell immunologist running personalised neoantigen vaccine trials.

Ramon E. Parsons
Director, Tisch Cancer Institute; Chair, Department of Oncological Sciences
PTEN and PI3K signallingBreast cancer geneticsTumour suppressors

Discovered the tumour-suppressor gene PTEN, one of the most frequently lost genes in cancer.

Sundar Jagannath
Director, Center of Excellence for Multiple Myeloma
Multiple myelomaNovel agentsBispecific antibodies

Veteran myeloma trialist who helped bring proteasome inhibitors and bispecifics to patients.

Thomas U. Marron
Director, Early Phase Trials Unit
Neoadjuvant immunotherapyLiver cancerPhase 1 trials

Showed that neoadjuvant immunotherapy can produce major pathologic responses in liver cancer.

Key papers

1top
rctNew England Journal of Medicine 2024changed practice
NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer

Patients fit enough for cisplatin whose bladder cancer has invaded the muscle wall should now be offered durvalumab with their pre-operative chemotherapy and for about a year after surgery, which improves the chance of cure without compromising the operation. The trial cannot say whether the adjuvant phase is necessary, or how to treat cisplatin-ineligible patients, for whom other trials are ongoing.

Connected

14top

cancers

2
Bladder & urothelial cancerMultiple myeloma

pathways

1
Tumour dormancy

ideas

3
Keep them asleep: dormancy maintenance as adjuvant therapyTurn one tumour into a vaccine to treat all the othersWhat decides which disseminated cells ever colonise?

people

7
Joshua BrodyMatthew D. GalskyMiriam MeradNina BhardwajRamon E. ParsonsSundar JagannathThomas U. Marron

key papers

1
NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer